Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female melanoma patient.

Gambichler T, Susok L, Fels M, Schneider-Gold C, Hof Zum Berge F, Stockfleth E, Ayzenberg I.

Br J Dermatol. 2019 Jul 19. doi: 10.1111/bjd.18358. [Epub ahead of print]

PMID:
31325163
2.

Understanding the burden of refractory myasthenia gravis.

Schneider-Gold C, Hagenacker T, Melzer N, Ruck T.

Ther Adv Neurol Disord. 2019 Mar 1;12:1756286419832242. doi: 10.1177/1756286419832242. eCollection 2019. Review.

3.

Tracking the brain in myotonic dystrophies: A 5-year longitudinal follow-up study.

Gliem C, Minnerop M, Roeske S, Gärtner H, Schoene-Bake JC, Adler S, Witt JA, Hoffstaedter F, Schneider-Gold C, Betz RC, Helmstaedter C, Tittgemeyer M, Amunts K, Klockgether T, Weber B, Kornblum C.

PLoS One. 2019 Mar 7;14(3):e0213381. doi: 10.1371/journal.pone.0213381. eCollection 2019.

4.

Reduction of Cellular Nucleic Acid Binding Protein Encoded by a Myotonic Dystrophy Type 2 Gene Causes Muscle Atrophy.

Wei C, Stock L, Schneider-Gold C, Sommer C, Timchenko NA, Timchenko L.

Mol Cell Biol. 2018 Jun 28;38(14). pii: e00649-17. doi: 10.1128/MCB.00649-17. Print 2018 Jul 15.

5.

Mechanical thrombectomy in a young stroke patient with Duchenne muscular dystrophy.

Spicher C, Schneider R, Mönnings P, Schneider-Gold C, Kallenberg D, Cevik B, Lukas C, Gold R, Krogias C.

Ther Adv Neurol Disord. 2018 Mar 1;11:1756286418759188. doi: 10.1177/1756286418759188. eCollection 2018.

6.

CASQ1 mutations impair calsequestrin polymerization and cause tubular aggregate myopathy.

Böhm J, Lornage X, Chevessier F, Birck C, Zanotti S, Cudia P, Bulla M, Granger F, Bui MT, Sartori M, Schneider-Gold C, Malfatti E, Romero NB, Mora M, Laporte J.

Acta Neuropathol. 2018 Jan;135(1):149-151. doi: 10.1007/s00401-017-1775-x. Epub 2017 Oct 16. No abstract available.

PMID:
29039140
7.

Monozygotic twins with a new compound heterozygous SPG11 mutation and different disease expression.

Schneider-Gold C, Dekomien G, Regensburger M, Schneider R, Trampe N, Krogias C, Lukas C, Bellenberg B.

J Neurol Sci. 2017 Oct 15;381:265-268. doi: 10.1016/j.jns.2017.09.005. Epub 2017 Sep 5.

PMID:
28991695
8.

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

Schneider-Gold C, Reinacher-Schick A, Ellrichmann G, Gold R.

Ther Adv Neurol Disord. 2017 Oct;10(10):339-341. doi: 10.1177/1756285617721093. Epub 2017 Jul 26. No abstract available.

9.

Severe refractory CIDP: a case series of 10 patients treated with bortezomib.

Pitarokoili K, Yoon MS, Kröger I, Reinacher-Schick A, Gold R, Schneider-Gold C.

J Neurol. 2017 Sep;264(9):2010-2020. doi: 10.1007/s00415-017-8599-4. Epub 2017 Aug 23.

PMID:
28836002
10.

Unilateral right prosopometamorphopsia with positive "half-face-covering-test" after small occipitotemporal stroke.

Schroeder C, Schneider-Gold C, Behrendt V, Grüter T, Lukas C, Gold R, Krogias C.

J Neurol Sci. 2017 Aug 15;379:247-248. doi: 10.1016/j.jns.2017.06.025. Epub 2017 Jun 16. No abstract available.

PMID:
28716251
11.

Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.

Ellrichmann G, Gold R, Ayzenberg I, Yoon MS, Schneider-Gold C.

Ther Adv Neurol Disord. 2017 Feb;10(2):91-101. doi: 10.1177/1756285616679369. Epub 2016 Dec 9.

12.

[Radiation-Induced Radiculopathy with Paresis of the Neck and Autochthonous Back Muscles with Additional Myopathy].

Ellrichmann G, Lukas C, Adamietz IA, Grunwald C, Schneider-Gold C, Gold R.

Fortschr Neurol Psychiatr. 2016 Jun;84(6):363-7. doi: 10.1055/s-0042-108195. Epub 2016 Jul 8. German.

PMID:
27391986
13.

Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration.

Schneider-Gold C, Krenzer M, Klinker E, Mansouri-Thalegani B, Müllges W, Toyka KV, Gold R.

Ther Adv Neurol Disord. 2016 Jul;9(4):297-303. doi: 10.1177/1756285616637046. Epub 2016 Mar 10.

14.

Diagnostic support for selected neuromuscular diseases using answer-pattern recognition and data mining techniques: a proof of concept multicenter prospective trial.

Grigull L, Lechner W, Petri S, Kollewe K, Dengler R, Mehmecke S, Schumacher U, Lücke T, Schneider-Gold C, Köhler C, Güttsches AK, Kortum X, Klawonn F.

BMC Med Inform Decis Mak. 2016 Mar 8;16:31. doi: 10.1186/s12911-016-0268-5.

15.

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H.

J Neurol. 2016 Aug;263(8):1473-94. doi: 10.1007/s00415-016-8045-z. Epub 2016 Feb 17. Review.

16.

Cortical and Subcortical Grey and White Matter Atrophy in Myotonic Dystrophies Type 1 and 2 Is Associated with Cognitive Impairment, Depression and Daytime Sleepiness.

Schneider-Gold C, Bellenberg B, Prehn C, Krogias C, Schneider R, Klein J, Gold R, Lukas C.

PLoS One. 2015 Jun 26;10(6):e0130352. doi: 10.1371/journal.pone.0130352. eCollection 2015.

17.

SonoGraphic monitoring of severe focal B-cell myositis of the anterior calf muscle responsive to rituximab.

Schneider-Gold C, Krogias C, Neusch C, Hasselblatt M, Gold R.

Muscle Nerve. 2015 Nov;52(5):911-3. doi: 10.1002/mus.24751. No abstract available.

PMID:
26112150
18.

Evaluation of CNS involvement in myotonic dystrophy type 1 and type 2 by transcranial sonography.

Krogias C, Bellenberg B, Prehn C, Schneider R, Meves SH, Gold R, Lukas C, Schneider-Gold C.

J Neurol. 2015 Feb;262(2):365-74. doi: 10.1007/s00415-014-7566-6. Epub 2014 Nov 11.

PMID:
25385052
19.

Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab.

Krogias C, Hoepner R, Müller A, Schneider-Gold C, Schröder A, Gold R.

JAMA Neurol. 2013 Aug;70(8):1056-9. doi: 10.1001/jamaneurol.2013.143.

PMID:
23778873
20.

GSK3β mediates muscle pathology in myotonic dystrophy.

Jones K, Wei C, Iakova P, Bugiardini E, Schneider-Gold C, Meola G, Woodgett J, Killian J, Timchenko NA, Timchenko LT.

J Clin Invest. 2012 Dec;122(12):4461-72. doi: 10.1172/JCI64081. Epub 2012 Nov 19.

21.

Late-onset myopathy of the posterior calf muscles mimicking Miyoshi myopathy unrelated to dysferlin mutation: a case report.

Neusch C, Kuhlmann T, Kress W, Schneider-Gold C.

J Med Case Rep. 2012 Oct 10;6:345. doi: 10.1186/1752-1947-6-345.

22.

The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease.

Minnerop M, Weber B, Schoene-Bake JC, Roeske S, Mirbach S, Anspach C, Schneider-Gold C, Betz RC, Helmstaedter C, Tittgemeyer M, Klockgether T, Kornblum C.

Brain. 2011 Dec;134(Pt 12):3530-46. doi: 10.1093/brain/awr299. Epub 2011 Nov 29.

23.

RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2.

Jones K, Jin B, Iakova P, Huichalaf C, Sarkar P, Schneider-Gold C, Schoser B, Meola G, Shyu AB, Timchenko N, Timchenko L.

Am J Pathol. 2011 Nov;179(5):2475-89. doi: 10.1016/j.ajpath.2011.07.013. Epub 2011 Sep 1.

24.

Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 (DM1) cells.

Huichalaf C, Sakai K, Jin B, Jones K, Wang GL, Schoser B, Schneider-Gold C, Sarkar P, Pereira-Smith OM, Timchenko N, Timchenko L.

FASEB J. 2010 Oct;24(10):3706-19. doi: 10.1096/fj.09-151159. Epub 2010 May 17.

25.

CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2.

Schneider-Gold C, Timchenko LT.

Rev Neurosci. 2010;21(1):19-28. Review.

PMID:
20458885
26.

Side effects of anesthesia in DM2 as compared to DM1: a comparative retrospective study.

Kirzinger L, Schmidt A, Kornblum C, Schneider-Gold C, Kress W, Schoser B.

Eur J Neurol. 2010 Jun 1;17(6):842-5. doi: 10.1111/j.1468-1331.2009.02942.x. Epub 2010 Jan 20.

PMID:
20100232
27.

Unusual Charcot-Marie-Tooth phenotype due to a mutation within the intracellular domain of myelin protein zero.

Schneider-Gold C, Kötting J, Epplen JT, Gold R, Gerding WM.

Muscle Nerve. 2010 Apr;41(4):550-4. doi: 10.1002/mus.21523.

PMID:
19882637
28.

Reduction of the rate of protein translation in patients with myotonic dystrophy 2.

Huichalaf C, Schoser B, Schneider-Gold C, Jin B, Sarkar P, Timchenko L.

J Neurosci. 2009 Jul 15;29(28):9042-9. doi: 10.1523/JNEUROSCI.1983-09.2009.

29.

Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patients.

Salisbury E, Schoser B, Schneider-Gold C, Wang GL, Huichalaf C, Jin B, Sirito M, Sarkar P, Krahe R, Timchenko NA, Timchenko LT.

Am J Pathol. 2009 Aug;175(2):748-62. doi: 10.2353/ajpath.2009.090047. Epub 2009 Jul 9.

30.

Grey and white matter loss along cerebral midline structures in myotonic dystrophy type 2.

Minnerop M, Luders E, Specht K, Ruhlmann J, Schneider-Gold C, Schröder R, Thompson PM, Toga AW, Klockgether T, Kornblum C.

J Neurol. 2008 Dec;255(12):1904-9. doi: 10.1007/s00415-008-0997-1. Epub 2008 Sep 3.

31.

Current and future standards in treatment of myasthenia gravis.

Gold R, Schneider-Gold C.

Neurotherapeutics. 2008 Oct;5(4):535-41. doi: 10.1016/j.nurt.2008.08.011. Review.

32.

LGMD 2I due to the common mutation 826C>A in the FKRP gene presenting as myopathy with vacuoles and paired-helical filaments.

Reilich P, Petersen JA, Vielhaber S, Mawrin C, Schneider-Gold C, Sommer C, Reiners K, Deschauer M, Pongratz D, Lochmüller H, Walter MC.

Acta Myol. 2006 Oct;25(2):73-6.

PMID:
18593008
33.

Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1.

Salisbury E, Sakai K, Schoser B, Huichalaf C, Schneider-Gold C, Nguyen H, Wang GL, Albrecht JH, Timchenko LT.

Exp Cell Res. 2008 Jul 1;314(11-12):2266-78. doi: 10.1016/j.yexcr.2008.04.018. Epub 2008 May 10.

34.

Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.

Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R.

Muscle Nerve. 2008 Mar;37(3):406-9.

PMID:
17918749
35.

Mitofusin 2 gene mutation (R94Q) causing severe early-onset axonal polyneuropathy (CMT2A).

Neusch C, Senderek J, Eggermann T, Elolff E, Bähr M, Schneider-Gold C.

Eur J Neurol. 2007 May;14(5):575-7.

PMID:
17437620
36.

Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease?

Neusch C, Bähr M, Schneider-Gold C.

Muscle Nerve. 2007 Jun;35(6):712-24. Review.

PMID:
17373702
37.

Phenotypic spectrum of PINK1-associated parkinsonism in 15 mutation carriers from 1 family.

Hiller A, Hagenah JM, Djarmati A, Hedrich K, Reetz K, Schneider-Gold C, Kress W, Münchau A, Klein C.

Mov Disord. 2007 Jan;22(1):145-7.

PMID:
17013904
38.

Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?

Hedrich K, Hagenah J, Djarmati A, Hiller A, Lohnau T, Lasek K, Grünewald A, Hilker R, Steinlechner S, Boston H, Kock N, Schneider-Gold C, Kress W, Siebner H, Binkofski F, Lencer R, Münchau A, Klein C.

Arch Neurol. 2006 Jun;63(6):833-8.

PMID:
16769864
39.

[Musculoskeletal pain as the most prominent feature in myotonic dystrophy type 2].

George A, Schneider-Gold C, Reiners K, Sommer C.

Schmerz. 2006 Sep;20(5):388, 390-4, 396-7. German.

PMID:
16758212
40.

Pregnancy and delivery of a healthy baby in autoimmune Lambert-Eaton myasthenic syndrome.

Schneider-Gold C, Wessig C, Höpker M, Erdlenbruch B, Gold R, Toyka K.

J Neurol. 2006 Sep;253(9):1236-7. Epub 2006 Apr 5. No abstract available.

PMID:
16598612
41.

Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases.

Schneider-Gold C, Hartung HP, Gold R.

Muscle Nerve. 2006 Sep;34(3):284-91. Review.

PMID:
16583368
42.

Outcome and effect of pregnancy in myotonic dystrophy type 2.

Rudnik-Schöneborn S, Schneider-Gold C, Raabe U, Kress W, Zerres K, Schoser BG.

Neurology. 2006 Feb 28;66(4):579-80.

PMID:
16505316
43.

Corticosteroids for myasthenia gravis.

Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002828. Review.

PMID:
15846640
44.

Sudden cardiac death in myotonic dystrophy type 2.

Schoser BG, Ricker K, Schneider-Gold C, Hengstenberg C, Dürre J, Bültmann B, Kress W, Day JW, Ranum LP.

Neurology. 2004 Dec 28;63(12):2402-4. Review.

PMID:
15623712
45.

Musculoskeletal pain in patients with myotonic dystrophy type 2.

George A, Schneider-Gold C, Zier S, Reiners K, Sommer C.

Arch Neurol. 2004 Dec;61(12):1938-42.

PMID:
15596616
46.

Cardiac and skeletal muscle involvement in myotonic dystrophy type 2 (DM2): a quantitative 31P-MRS and MRI study.

Schneider-Gold C, Beer M, Köstler H, Buchner S, Sandstede J, Hahn D, Toyka KV.

Muscle Nerve. 2004 Nov;30(5):636-44.

PMID:
15452841
47.

Muscle pathology in 57 patients with myotonic dystrophy type 2.

Schoser BG, Schneider-Gold C, Kress W, Goebel HH, Reilich P, Koch MC, Pongratz DE, Toyka KV, Lochmüller H, Ricker K.

Muscle Nerve. 2004 Feb;29(2):275-81.

PMID:
14755494
48.

[Myasthenia gravis: pathology, diagnosis and treatment].

Schneider-Gold C, Hartung HP.

Fortschr Neurol Psychiatr. 2004 Jan;72(1):45-56; quiz 56-7. Review. German. No abstract available.

PMID:
14745689
49.

Oculomotor signs in Lambert-Eaton myasthenic syndrome-coincidence with myasthenia gravis.

Toyka KV, Schneider-Gold C.

Ann Neurol. 2003 Jul;54(1):135-6; author reply 136-7. No abstract available.

PMID:
12838533
50.

Neuroleptic malignant syndrome in Kufs' disease.

Reif A, Schneider MF, Hoyer A, Schneider-Gold C, Fallgatter AJ, Roggendorf W, Pfuhlmann B.

J Neurol Neurosurg Psychiatry. 2003 Mar;74(3):385-7.

Supplemental Content

Loading ...
Support Center